SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc. (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), a biopharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical products, today announced that one of its clinical investigators will present data from a Phase II clinical study of MN-001, MediciNova's investigational oral treatment for bronchial asthma. As previously announced, MN-001 was well tolerated and significantly improved measures of respiratory function in asthma patients compared to placebo in this trial.
Dr. William W. Busse, Professor and Chairman of the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, will present the poster "Effects of MN-001 in Patients with Mild-to-Moderate Asthma in a Randomized, Double-Blind and Placebo-Controlled Phase II Study" at the 2007 Annual Meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) on Saturday, February 24, 2007, in San Diego.
About MediciNova
MediciNova, Inc. is a biopharmaceutical company that acquires well characterized small-molecule drugs through strategic alliances with Japanese and other international pharmaceutical companies and accelerates their development in a diversified portfolio of therapeutic product candidates targeting significant disease markets. MediciNova's pipeline, which includes six compounds in clinical testing, targets a variety of prevalent medical conditions, including asthma, multiple sclerosis, status asthmaticus, interstitial cystitis, solid tumors, Generalized Anxiety Disorder, insomnia, preterm labor, urinary incontinence and thrombotic disorders. For more information on MediciNova, Inc., please visit www.medicinova.com.
The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135
This press release may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding clinical trials supporting efficacy of one of our product candidates as well as the potential novelty of that candidate as a treatment for disease. These statements are based on certain assumptions made by the Company's management that are believed to be reasonable at the time. Such statements are subject to a number of risks and uncertainties, many of which are beyond the control of the Company, including the results of clinical studies and other risks and uncertainties, including those described in the Company's filings with the Securities and Exchange Commission. These assumptions, risks and uncertainties could cause the Company's actual results to differ materially from those implied or expressed by the forward-looking statements.